Vol. 3 No. 2 (2025)

Volume 3, Issue 2 spans cardiology, orthopedics, neurology and ophthalmology. It reviews PCSK9 inhibitors as lipid-lowering therapy for atherosclerotic cardiovascular disease and explores biocompatible magnesium alloys as emerging materials for mitigating muscle degeneration and promoting regeneration. Neurological care is addressed through a nutrition-based approach to Parkinson's disease management, while an editorial raises safety questions about repeated low-level red light therapy in children with myopia. The issue also provides a comprehensive overview of central serous chorioretinopathy, covering pathogenesis, diagnosis and treatment. Together, the articles reflect diverse therapeutic strategies from molecular targets to clinical practice.